U.S. Sanctions Former DR Congo President Joseph Kabila Over Rebel Support 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
U.S. Fast-Tracks $8.6 Billion Arms Sales to Middle East Allies Amid Rising Tensions 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
U.S. Flags Vietnam as “Priority Foreign Country” Over Intellectual Property Concerns 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
US Adds European Union to Section 301 Watchlist Amid Trade Concerns 
US House Advances $70 Billion Immigration Enforcement Budget Plan 
Trump Expands Cuba Sanctions Targeting Key Sectors and Foreign Entities 
US to Withdraw 5,000 Troops from Germany Amid Growing Rift with European Allies 
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Agios Pharmaceuticals has announced a major regulatory milestone with the U.S. Food and Drug Administration approving mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia. The approval represents a significant advancement for patients living with these inherited blood disorders, many of whom face lifelong complications related to chronic anemia and frequent blood transfusions.
Mitapivat, an oral therapy developed by Agios, is designed to address the underlying metabolic pathways involved in red blood cell function. The FDA’s decision was supported by strong data from Phase 3 clinical trials, which demonstrated that the treatment significantly improved hemoglobin levels in adult patients with alpha- or beta-thalassemia. In addition to increasing hemoglobin, the trials showed a meaningful reduction in transfusion burden, an outcome that could greatly improve quality of life for patients who currently depend on regular transfusions.
According to the company, mitapivat is expected to become available to eligible patients in late January 2026. This timeline reflects the need to implement a Risk Evaluation and Mitigation Strategy (REMS) program, a requirement set by the FDA to ensure the safe use of the medication. REMS programs are typically mandated when specific safety risks need to be carefully managed through monitoring, education, or controlled distribution.
While the overall clinical trial results were positive, Agios also disclosed safety findings observed during development. Five patients participating in the trials experienced adverse reactions that suggested hepatocellular injury. These cases were closely evaluated and factored into the FDA’s benefit-risk assessment, ultimately leading to the approval with additional safety oversight through the REMS program.
The FDA approval of mitapivat marks an important step forward in the treatment landscape for thalassemia-related anemia. As the first therapy of its kind approved for both alpha- and beta-thalassemia in adults, mitapivat offers new hope for reducing disease burden and improving long-term outcomes. With its upcoming launch and safety measures in place, the therapy is poised to play a key role in addressing unmet needs within the thalassemia community.
